Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 56.25% and 40.58%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Landmine No. 1: Smaller biotech companies short on cash will face a funding crunch if the stock market stays down. How to diffuse it: Favor biotech companies that just raised cash, or have enough on hand to cover at least 18 months of cash burn, says Jefferies biotech analyst Michael Yee. Several companies were lucky enough to raise capital right before the biotech group started to fall apart on March 6.

Pieris Pharmaceuticals (PIRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pieris Pharmaceuticals (PIRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NEW YORK, NY / ACCESSWIRE / March 24, 2020 / Solebury Trout, a boutique investor relations and corporate communications firm, announced today that it will be hosting a Virtual Conference Series on March ...

Shares of Pieris Pharmaceuticals (NASDAQ:PIRS) remained unaffected at $2.91 after the company reported Q1 results.Quarterly Results Earnings per share rose 65.00% year over year to ($0.07), which beat the estimate of ($0.17).Revenue of $13,261,000 up by 55.19% year over year, which beat the estimate of $8,840,000.Guidance Earnings guidance hasn't been issued by the company for now.View more earnings on PIRSPieris Pharmaceuticals hasn't issued any revenue guidance for the time being.Recent Stock Performance Company's 52-week high was at $6.04Company's 52-week low was at $1.60Price action over last quarter: Up 34.72%Company Profile Pieris Pharmaceuticals Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of Anticalin class of biotherapeutics. Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. The company with the help of technology creates differentiated drugs such as PRS-080, PRS-060, PRS-343 and PRS-332 that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with a high unmet medical need. Geographically, all the operation of the firm is functioned through the region of United States.See more from Benzinga * Recap: CONSOL Coal Resources Q1 Earnings * Ready Capital: Q1 Earnings Insights * Recap: Gogo Q1 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

BOSTON, MA / ACCESSWIRE / January 8, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced an update to its senior leadership team. Within research and development, Ingmar Bruns, M.D., Ph.D., previously serving as Vice President, Clinical Development at Pieris, has been appointed to the position of Senior Vice President, Head of Clinical Development, responsible for overseeing clinical strategy, clinical operations and regulatory affairs; and Shane Olwill, Ph.D., previously serving as Vice President, Development and Immuno-Oncology at Pieris, has been appointed to the position of Senior Vice President, Head of Translational Science, responsible for overseeing target selection and general translational endeavors, including preclinical and clinical biomarker development.

Q1 2020 Pieris Pharmaceuticals Inc Earnings Call

Company to Host an Investor Conference Call on Monday, May 11, 2020 at 8:00 Am Edt BOSTON, MA / ACCESSWIRE / May 11, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company ...

BOSTON, MA / ACCESSWIRE / March 23, 2020 / Pieris Pharmaceuticals, Inc. (PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory, cancer, and other diseases, today announced an update on its strategic immuno-oncology collaboration with Servier, originally established in 2017. After conducting an extensive portfolio review, Servier has decided to focus on continued and accelerated development of the two most advanced programs, including PRS-344/S095012, and to discontinue development of the two earlier-stage programs in the collaboration. Pieris and Servier will continue the development of PRS-344/S095012, a 4-1BB/PD-L1 bispecific and the lead program in the collaboration.

One simple way to benefit from the stock market is to buy an index fund. But if you pick the right individual stocks...

A webcast of the Company's presentation will be available at this link. Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) just released its latest first-quarter results and things are looking...

There's been a major selloff in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) shares in the week since it released its...

BOSTON, MA / ACCESSWIRE / May 28, 2020 / Pieris Pharmaceuticals, Inc. (PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, announced today that management will present at the Jefferies 2020 Virtual Healthcare Conference on Thursday, June 4, 2020 at 3:30 PM EDT. Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.

Full Year 2019 Pieris Pharmaceuticals Inc Earnings Call

BOSTON, MA / ACCESSWIRE / May 4, 2020 / Pieris Pharmaceuticals, Inc. (PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that it will host a first quarter 2020 investor call on Monday, May 11, 2020 at 8:00 AM EDT to discuss financial results and provide a corporate update. Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON THURSDAY, MARCH 12, 2020 AT 8:00 AM EDT BOSTON, MA / ACCESSWIRE / March 12, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology ...

BOSTON, MA / ACCESSWIRE / March 5, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology ...